Trial Profile
A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Registrational; Therapeutic Use
- Acronyms SUNSHINE
- Sponsors Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals
- 31 Oct 2023 According to a Novartis media release, based on analyses from the largest Phase III program in HS to date, SUNSHINE and SUNRISE study the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults
- 01 Jun 2023 According to a Novartis media release, based on results from this trial, the European Commission (EC) has approved Cosentyx (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to conventional systemic HS therapy.
- 26 Apr 2023 According to a Novartis media release, regulatory decision from the US Food and Drug Administration (FDA) expected later this year. Also, The recommendation for Cosentyx in HS will be referred to the European Commission, which is expected to deliver a final decision within 2 months.